Pfizer Chairman and CEO Albert Bourla did not mince his words at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on Monday regarding the controversial positions that Robert F.

When Galapagos and Gilead Sciences entered a global drug R&D collaboration six years ago, the deal focused on Galapagos’s capabilities as a developer of small molecule drugs. Fast forward to ...

HHS is proposing major changes to HIPAA for the first time in more than a decade, aiming to strengthen cybersecurity ...

Solera Health's $40 million Series E round was co-led by Health Care Service Corporation and included participation from ...

Imagine pulling up to a new restaurant on Friday night. It has had wonderful reviews, and you are excited to try it. But a ...

Patient flow automation startup Qventus closed a $105 million Series D financing round. The company’s technology is used by ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Healthcare AI company Innovaccer closed a $275 million Series F funding round, bringing its fundraising total to date to $675 ...

Technology often plays a critical role in strategies to combat rising costs while maintaining quality care. Here are four ...

INVEST is the flagship event for MedCity News, bringing together healthcare and life science investors, startups and stakeholders in one venue to network and talk about innovations shaping the ...